PROCEPT BioRobotics Corporation filings document the public-company disclosures of a Nasdaq-listed surgical robotics business focused on urology. Recent Form 8-K reports furnish quarterly financial results, revenue and operating commentary, investor presentation materials, and updates tied to the company’s AQUABEAM and HYDROS Robotic Systems, Aquablation therapy, and related product and clinical programs.
Proxy and governance filings cover board composition, committee assignments, director independence, executive compensation, equity awards, and severance or change-of-control arrangements. The filings also identify PRCT common stock registered under Section 12(b) and traded on The Nasdaq Global Market.
PROCEPT BioRobotics Corp (PRCT) had a Form 144 filed on behalf of stockholder Alaleh Nouri indicating an intended sale of 297 shares of common stock through Fidelity Brokerage Services LLC on or after September 9, 2026, under Rule 144.
The shares relate to a restricted stock vesting event on September 8, 2026, received from the issuer as compensation. The filer notes that the sale includes an amount necessary to cover a tax obligation arising from settlement of the vested equity award. Reported outstanding common shares total 57,273,659.
PROCEPT BioRobotics Corp (PRCT) has a planned sale of common stock reported for the account of officer Barry L. Templin under Rule 144. The notice covers the potential sale of 373 shares of common stock, with the shares originating from restricted stock vesting on September 8, 2026.
The shares are held at Fidelity Brokerage Services LLC, and the remarks state that the sale includes an amount needed to satisfy a tax obligation from the settlement of a vested equity award distribution. Fidelity signed as attorney-in-fact for Barry L. Templin.
PROCEPT BioRobotics Corp (PRCT) has a notice under Rule 144 indicating that officer Kevin Waters may sell up to 373 shares of the company’s common stock through Fidelity Brokerage Services LLC on NASDAQ.
The shares relate to restricted stock that vested on September 8, 2026, and the planned sale includes an amount to cover a tax obligation arising from the settlement of this vested equity award.
PROCEPT BioRobotics Corp executive Nouri Alaleh reported equity compensation awards on August 13, 2026. He received 22,965 shares of Common Stock in the form of restricted stock units (RSUs), each representing one share, increasing his direct Common Stock holdings to 128,034 shares after the grant.
Alaleh was also granted a Stock Option for 31,773 shares of Common Stock at an exercise price of $21.95 per share, expiring on August 12, 2036, bringing his directly held stock options from this grant to 31,773. The RSUs vest 25% on August 13, 2027, with the remaining three-quarters vesting quarterly over 36 months, while 1/48th of the option shares vest monthly from August 13, 2026 over four years, in each case subject to continued service. Both awards are intended to represent 50% of the value of his expected 2027 grant, made in lieu of that portion of the future grant.
PROCEPT BioRobotics Corp reported compensation-related equity awards to EVP and Chief Technology Officer Barry L. Templin. On August 13, 2026, he received a grant of 36,312 stock options with an exercise price of $21.95 per share, expiring on August 12, 2036. These options vest 1/48 monthly starting August 13, 2026, over four years, subject to continued service.
On the same date, he was also granted 26,246 restricted stock units (RSUs), each representing one share of common stock. One-quarter of the RSUs vest on August 13, 2027, with the remainder vesting quarterly over 36 months, contingent on continued service. Following the RSU grant, he directly holds 95,199 common shares. Both awards are intended to represent 50% of the value of his expected 2027 grant and are made in lieu of that portion.
PROCEPT BioRobotics Corp reports that EVP and CFO Kevin Waters received equity awards on August 13, 2026. He was granted 29,527 RSUs, each representing a contingent right to one share of common stock, bringing his directly held common shares to 180,728. He also received a stock option for 40,851 shares of common stock at an exercise price of $21.95 per share, expiring on August 12, 2036, with 40,851 option shares outstanding after the grant.
The RSUs vest with one-quarter on August 13, 2027 and the remainder in equal quarterly installments over 36 months, subject to continued service. The option vests in 1/48th monthly installments starting August 13, 2026 over four years, also subject to continued employment or service. Both awards are intended to represent 50% of the value of Waters’ expected 2027 grant, in lieu of that portion of the 2027 award.
PROCEPT BioRobotics Corp reported that Chief Strat/Marketing Officer Pooja Sharma received equity awards on August 13, 2026. She was granted 23,622 restricted stock units, each representing one share of common stock, and a stock option for 32,681 shares at an exercise price of $21.95 per share, expiring August 12, 2036.
The RSUs vest 25% on August 13, 2027, with the remainder vesting quarterly over 36 months, subject to continued service. The option vests in equal monthly installments over four years starting August 13, 2026. Both grants are intended to represent 50% of the value of Sharma’s expected 2027 grant, made in lieu of that portion. Following these awards, she directly holds 111,181 shares of common stock.
PROCEPT BioRobotics Corp reported that President and CEO Larry L. Wood, through The Larry Wood Trust, purchased 23,900 shares of common stock on August 7, 2026 at a weighted average price of $20.85 per share, with individual trade prices ranging from $20.67 to $21.02. Following this transaction, the trust holds 23,900 shares indirectly, and Wood also holds 314,203 shares directly, which include 825 shares acquired on May 14, 2026 under the company’s 2021 Employee Stock Purchase Plan.
PROCEPT BioRobotics reported second quarter 2026 revenue of $94.5 million, up 19% year over year, driven by higher U.S. handpiece, system and international revenue. U.S. revenue reached $83.4 million, with U.S. procedures over 13,100, an increase of approximately 21%. The company delivered 65 U.S. HYDROS systems, including 14 replacements, and handpieces represented about 98% of U.S. procedures.
Gross margin improved to 66%, supported by higher U.S. pricing and a $2.9 million tariff refund, while operating expenses rose to $89.8 million as the company invested in its commercial organization, BPH platform innovation and the WATER IV prostate cancer trial. Net loss widened to $26.9 million (adjusted EBITDA loss $11.3 million), and cash, cash equivalents and restricted cash totaled approximately $231 million at June 30, 2026.
For full year 2026, PROCEPT reiterates revenue guidance of $390 million to $410 million and gross margin of about 65%, expects U.S. procedure volume of 54,000-56,000, and now forecasts an adjusted EBITDA loss of $35 million to $30 million. Management also highlighted record HYDROS placements, completion of enrollment in the WATER IV study and a strengthened AUA guideline recommendation for Aquablation therapy.